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Background: Estrogen plays an important role as an anti-inflammatory and neuroprotective agent in ischemic
stroke. In this study, we analyzed the effect of a polygenic risk score (PRS) constructed using inflammatory genes
and estradiol levels on the risk of ischemic stroke.
Methods: This case-control study was conducted with 624 ischemic stroke patients and 624 age- and gender-matched
controls. The PRS estimated the polygenic contribution of inflammatory genes from ischemic stroke susceptibility loci.
Estradiol levels were measured using a radioimmunoassay. High and low estradiol levels were defined according to the
log-transformed median estradiol levels in female and male controls.
Results: Subjects in the fourth quartile of the PRS had a significant 1.57-fold risk of ischemic stroke (95% confidence
interval [CI], 1.12 ~ 2.19), after adjusting for covariates compared to individuals in the lowest quartile. Compared to
individuals with high estradiol levels and a low PRS as the reference group, those exposed to low estradiol levels and a
high PRS had an increased risk of ischemic stroke (odds ratio, 3.35; 95% CI, 1.79 ~ 6.28). Similar results were also observed
in males when the analysis was stratified by gender.
Conclusions: Our data suggest that the PRS can be useful in evaluating a high risk of ischemic stroke among patients,
especially those exposed to low estradiol levels.
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Ischemic stroke accounts for 60% ~ 80% of all cerebro-
vascular diseases and is the third leading cause of death
and the most common cause of permanent disability in
developed countries and in Taiwan. Elucidation of the
mechanisms involved in preventing cerebrovascular
disease therefore remains an important research goal.
Neuroinflammation is a general process of several
neurodegenerative diseases and may play an important
role in the pathogenesis of ischemic stroke [1]. Inflam-* Correspondence: ychsieh@tmu.edu.tw; hychiou@tmu.edu.tw
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the important role of the innate immune system after an
injury to the brain [2]. In a setting of cerebral injury,
several transcription factors involved in the inflamma-
tory response, including nuclear factor (NF)-κB, are
activated, and subsequently proinflammatory genes, such
as tumor necrosis factor (TNF)-α, monocyte chemo-
tactic protein (MCP)-1, E-selectin, etc., are upregulated
[3, 4]. Among them, MCP-1 is thought to play a pivotal
role in the inflammatory process, since MCP-1 can
combine with chemotactic cytokine receptor (CCR)-2 to
activate macrophages and attract monocytes to the
injured brain [5]. Afterwards, the cell adhesion molecule,
E-selectin, increases in endothelial cells, damages the
endothelial barrier, and regulates the attachment and
transendothelial migration of leukocytes [6, 7].le is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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estrogen exposure can postpone the onset of aging and
reduce the risk of ischemic stroke and ischemic heart
disease [8, 9]. In addition, a growing body of evidence
suggests that estrogen has anti-inflammatory and neuro-
protective functions [10]. In vivo and in vitro studies
found that estradiol decreased expressions of MCP-1
and E-selectin [11, 12]. Several studies showed that de-
creases in estrogen-induced vascular inflammatory
markers, including cytokines and adhesion molecules,
might be the mechanism of vascular protection [13, 14].
Moreover, a novel and unique mechanism for the anti-
inflammatory activity of 17β-estradiol (E2) was found,
which indicated that E2 prevents inflammatory gene
transcription induced by inflammatory agents by inhibit-
ing NF-κB intracellular transport [15, 16].
Since estrogen can exert an antiatherosclerotic effect
through modifying inflammatory genes, that might be a
possible mechanism for its beneficial effect in cerebro-
vascular disease. In this study, we developed a polygenic
risk score (PRS) of inflammatory genes for ischemic
stroke and investigated the interaction between estradiol
levels and the PRS of inflammatory genes on the risk of
ischemic stroke.
Methods
Study design and participants
This case-control study was conducted with 624 ische-
mic stroke patients and 624 age- and gender-matched
controls. Ischemic stroke patients who had suffered a
first-ever episode of a symptomatic ischemic stroke and
had been admitted to the department of neurology at
National Taiwan University Hospital, Shuang Ho Hospital,
Chi-Mei Medical Center, Shin Kong Wu Ho-Su Memorial
Hospital, Tri-Service General Hospital, or Wanfang
Hospital, Taiwan, were recruited as cases. Ischemic stroke
was defined as a focal neurologic deficit of presumed
vascular cause with sudden onset and lasting for at least
24 h as a recent infarct in a clinically relevant area of the
brain on a computed tomographic (CT) or magnetic
resonance imaging (MRI) brain scan performed within
10 days of the event. Controls were recruited from a
community-based prospective study in Taipei which was
described in a previous study [17]. Some of the control
subjects were selected from those who attended an annual
health examination at the health center at Taipei Medical
University Hospital. After frequency matching by age and
gender with cases and excluding those with a history of
stroke or heart disease, 624 subjects were enrolled as con-
trols. In addition, participants were excluded if they were
taking hormone-related drugs. The study was approved by
the ethics committees of the participating hospitals and
Taipei Medical University with the understanding that
all data would be coded and patient anonymity wasguaranteed. Each subject provided written informed
consent prior to participation in the study.
Data collection and risk factor definition
Information pertaining to the age, gender, and presence
of major vascular risk factors was collected from patients
and controls using a structured questionnaire. The
height, weight, waist and hip circumferences, total chol-
esterol, triglyceride, high-density lipoprotein cholesterol
(HDL-C), low-density lipoprotein cholesterol (LDL-C),
and fasting glucose were measured. The body-mass
index (BMI) was defined as an individual’s body weight
(kg) divided by the square of their height (m2). The
waist-to-hip ratio (WHR) was computed using the index
of waist circumference divided by the hip circumference.
Subjects who had ever smoked at least 100 cigarettes
during their entire life were defined as a cigarette
smoker, while subjects who had drunk alcohol at least
once per day during a year were categorized as an alco-
hol drinker. These two factors were then combined for
analysis in the study. The above-mentioned information
was obtained in an interview with study subjects and a re-
view of medical charts by trained research assistants/
nurses. Hypertension was defined as systolic blood
pressure of >140 mmHg or diastolic blood pressure
of >90 mmHg or the use of antihypertensive drugs.
Diabetes was defined as fasting glucose of ≥126 mg/dL or
the use of pharmacological treatment.
Estradiol analyses
The laboratory assay for estradiol was a radioimmuno-
assay. The lower limit of quantitation was 2 pg/ml for
estradiol. Duplicate samples were included for 10% of
subjects for quality control purposes, and the coefficient
of variation was 8%. Samples were labeled in such a way
that laboratory personnel were unaware of the case-
control status of the samples or the identity of the dupli-
cates. In this study, although estradiol levels were mea-
sured for only 513 ischemic stroke patients and 383
healthy controls due to a limited research budget, char-
acteristics of study subjects did not differ between those
whose estradiol level was measured and those for whom
it was not. Additionally, estradiol concentrations were
log-transformed to reduce departures from a normal
distribution. High and low estradiol levels were defined ac-
cording to median log-transformed estradiol levels in pre-
menopausal or postmenopausal female and male controls.
DNA extraction, single-nucleotide polymorphism (SNP)
selection, and genotyping
Genomic DNA was extracted from EDTA-anticoagulated
peripheral blood according to the phenol chloroform
protocol and stored at -80 °C until used for further ana-
lysis. For the selection of SNPs, Haploview software was
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block analyses, using the Hapmap phase II genotype data
for inflammatory genes including MCP-1, CCR2, and
E-selectin in data of Han Chinese from Beijing, China.
Selection of tagSNPs was performed by running the tagger
program implemented in both the Haploview [18] and
tagSNPs programs [19]. The criteria for r2 was set to >0.8.
Another way to choose SNPs as tagSNPs was based on
SNPs located in the promoter region which might well
plausibly have a functional role. SNP genotyping was
performed using a polymerase chain reaction-restriction
fragment length polymorphism (PCR-RFLP) method. To
assure the genotyping quality, a detailed quality control
procedure including the duplicate identification of geno-
types, a Hardy-Weinberg Equilibrium (HWE) test, and a
call rate of >99% were measured. In total, 55 (5%) dupli-
cate samples were successfully genotyped, and the con-
cordance rate was 100%.
Polygenic risk score (PRS)
A PRS was used to evaluate polygenic susceptibility loci
which contributed to ischemic stroke, and was established
according to SNPs under a specified p-value threshold
(p < 0.15) on any one of the per-allele dominant or reces-
sive logistic regression models [20], which indicated a sig-
nificant main effect of polygenic risk for ischemic stroke.
When there was strong linkage disequilibrium between
SNPs located on the same gene, the variant with the low-
est p value was selected as the candidate. The total of the
product of the number of risk allele copies of candidate
SNPs and the corresponding log odds estimate were
subsequently measured as a weighted PRS. A multivariate
logistic regression model including the PRS, age, BMI,
hypertension, diabetes mellitus, heart disease, and stroke
family histories was utilized to explore the independent
association of the PRS with the risk of ischemic stroke.
Use of a bootstrap method with 1000 repetitions to adjust
model regression coefficients was to prevent a potential
overfitting issue. In this procedure, bootstrapping was re-
peatedly and randomly resampled by extracting samples
with replacement from the original dataset. Then cross-
validation and split-sample procedures were applied to en-
hance the accuracy of the prediction for internal validation
[21, 22]. In this step, the dataset was assigned to k subsets,
which formed the training set, and the holdout method
was repeated k times. The other k-1 subsets were merged
to constitute a training set. Moreover, we partitioned the
original dataset into training and validation samples,
including 80% and 20% of the original dataset, respectively.
Statistical analysis
Student’s t-test was used to compare continuous vari-
ables between cases and controls. The Chi-squared test
was applied to test differences in categorical variables. Amultivariate logistic regression model carried out with
adjustment for covariates, which significantly differed
between cases and controls in demographic and clinical
characteristics, was used to estimate odds ratios (ORs)
and 95% confidence intervals (CIs). HWE for each poly-
morphism was tested in the controls. Multiple testing
correlation was performed using the permutation test.
An additive effect of the estradiol level and PRS were
estimated using the relative excess risk resulting from
interaction (RERI). The power estimation of this gene-
environment interaction study was determined using the
QUANTO program [23]. All analyses were performed
with SAS Genetics software (vers. 9.4; SAS Institute,
Cary, NC, USA). Two-tailed p values were calculated,
and statistical significance was set to p < 0.05.
Results
Baseline characteristics of study subjects
Basic demographic and clinical characteristics of study
subjects are shown in Table 1. Mean ages of subjects
were 65.6 ± 10.8 years for cases and 65.0 ± 10.5 years for
controls. Ischemic stroke patients were significantly
more obese than healthy controls. The frequencies of
either one or both cigarette smoking/alcohol consump-
tion habits were significantly higher in patients than in
controls. Prominently higher percentages of hypertension,
diabetes mellitus, heart disease, and family stroke history
were observed for cases than for controls. The distribution
of estradiol levels in patients was significantly higher than
in healthy subjects for both females and males.
Association between inflammatory genes and ischemic
stroke risk
Genotype frequencies of MCP-1 (rs1024611 and
rs3760396), CCR2 (rs1799864 and rs1799865), and E-
selectin (rs2076059, rs10800469, rs3917412, and rs5368)
are depicted in Table 2. These SNPs were all under
HWE. There were no prominent associations between
SNPs on MCP-1, CCR2, or E-selectin genes in addition
to rs2076059, which was located on E-selectin and sig-
nificantly increased the risk of ischemic stroke under the
dominant model (Table 2).
Association between PRS and ischemic stroke risk
Concerning development of the PRS, four SNPs, namely
rs1024611, rs1799865, rs2076059, and rs5368, were
selected to create the PRS model. Since two SNPs
located on MCP-1 were in strong linkage disequilibrium
(D’ > 0.9) and both reached the criteria to be chosen as
candidate SNPs for the PRS, rs1024611 was picked due
to its lower p value. We choose two SNP, rs2076059 and
rs5368, on the same E-selectin gene because of low link-
age disequilibrium (D’ < 0.6) (Table 2).
Table 1 Demographic and clinical characteristics of the study population
Ischemic stroke patients Healthy control p value
N = 624 N = 624
Age (years) 65.6 ± 10.8 65.0 ± 10.5 - - -
Gender
Female 212 (34.0) 212 (34.0) - - -
Male 412 (66.0) 412 (66.0)
Body-mass index (kg/m2) 25.0 ± 3.9 24.6 ± 3.1 0.0212
Waist-hip ratio 0.94 ± 0.08 0.87 ± 0.07 <0.0001
Cigarette smoking/alcohol consumption
Never/Never 296 (47.6) 408 (65.8) <0.0001
Either one 203 (32.6) 177 (28.6)
Ever/Ever 123 (19.8) 35 (5.7)
Hypertension 482 (77.2) 371 (59.5) <0.0001
Diabetes mellitus 300 (48.1) 105 (16.8) <0.0001
Heart disease 163 (26.1) 109 (17.5) 0.0002
Dyslipidemia 476 (76.5) 504 (80.8) 0.0677
Family stroke history 149 (23.9) 97 (15.5) 0.0008
Estradiol levela
Female 155 2.90 (0.97) 128 1.68 (1.36) <0.0001
Male 358 3.18 (0.54) 255 2.97 (0.57) <0.0001
Data are presented as n (%) or mean ± standard deviation
aEstradiol level was shown in log transformed value
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subjects in the second (0.2033 ~ 0.3634), third (0.3635 ~
0.4933), and fourth quartiles (>0.4933) of the PRS had
1.12-, 1.17-, and 1.57-fold risks of ischemic stroke,
respectively, after adjusting for covariates compared to
individuals in the lowest quartile (Table 3).
Effects of estradiol level and PRS on ischemic stroke risk
Figure 1 indicates the effect of estradiol levels and the
PRS on the risk of ischemic stroke stratified by gender.Table 2 Association between inflammatory genes and the risk of isc




MCP-1 rs1024611 A/G 1.16(0.96–1.39) 0.1154b
rs3760396 C/G 0.93(0.69–1.27) 0.6585
CCR2 rs1799864 C/T 1.14(0.89–1.47) 0.3062
rs1799865 C/T 1.06(0.87–1.29) 0.5615
E-selectin rs2076059 T/C 1.26(0.96–1.66) 0.0950
rs10800469 A/G 1.02(0.86–1.22) 0.8060
rs3917412 A/G 1.00(0.82–1.21) 0.9769
rs5368 T/C 1.11(0.90–1.38) 0.3368
Abbreviations: OR odds ratio, CI confidence interval
aORs were adjusted for age, body-mass index, cigarette smoking/alcohol consumpt
bIncluded in the polygenic risk scoreRelative to people with high estradiol levels and a lower
PRS as the reference group, those with either risk factor
had increased risk of ischemic stroke, while subjects
exposed to a low estradiol level and a higher PRS had a
significant 3.35-fold risk of ischemic stroke (95% CI,
1.79 ~ 6.28, p = 0.0002). An additive interaction effect
was observed; however the statistic did not reach sig-
nificance due to the small sample size (RERI = 0.36;
95% CI, -0.96 ~ 1.68). A similar tendency was observed
for males when the analysis was stratified by gender.hemic stroke
Dominant model p value Recessive model p value
1.23(0.93–1.63) 0.1492 1.19(0.87–1.64) 0.2753
1.02(0.73–1.43) 0.9120 0.29(0.09–1.26) 0.1420
1.36(0.67–2.74) 0.3922 1.15(0.84–1.56) 0.3851
1.00(0.77–1.31) 0.9882 1.27(0.85–1.91) 0.1424b
1.37(1.01–1.84) 0.0411b 0.73(0.26–2.08) 0.5605
0.97(0.74–1.28) 0.8266 1.11(0.85–1.50) 0.5074
0.92(0.71–1.19) 0.5150 1.28(0.84–1.94) 0.2553
0.78(0.42–1.42) 0.4118 1.22(0.94–1.58) 0.1330b
ion, hypertension, diabetes mellitus, heart disease, and stroke family history
Table 3 Association between the polygenic risk score and the
risk of ischemic stroke
Polygenic risk score quartiles Total
Cases/Controls ORa (95% CI) P-value
1st 254/300 1.0
2nd 112/114 1.12(0.75–1.65) 0.5801
3rd 74/77 1.17(0.75–1.84) 0.5029
4th 184/133 1.57(1.12–2.19) 0.0084
p for trend 0.0050
aAdjusted for age, body mass index, cigarette smoking/alcohol consumption,
hypertension, diabetes mellitus, heart disease, and stroke family history
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In this study, we attempted to investigate the interaction
between estradiol levels and inflammatory genes includ-
ing MCP-1, CCR2, and E-selectin on the risk of ischemic
stroke. The PRS was developed and included four of
eight SNPs examined. A higher score indicated a higher
risk of ischemic stroke. The risk was exacerbated when a
subject was exposed to a low estradiol level and had a
higher PRS.
MCP-1, which is located on chromosome 17q11-21
and is composed of three exons and two introns, belongs
to the chemotactic cytokine family. MCP-1 -2518A > G
(rs1024611) and -927G > C (rs3760396) situated in the
distal promoter regulatory region of the MCP-1 gene
could affect the transcription of MCP-1 [24]. Two recentFig. 1 Combined effect of estradiol levels and polygenic risk score on the
cigarette smoking/alcohol consumption, hypertension, diabetes mellitus, he
high and low groups according to median log-transformed estradiol levels
risk score in controls was used as a cutoff pointmeta-analysis studies suggested that MCP-1 rs1024611
is associated with ischemic heart disease and ischemic
stroke susceptibilities [25, 26]. Furthermore, cerebral in-
farction patients had higher levels of serum MCP-1 than
did healthy control subjects; however, two SNPs,
rs1024611 and rs3760396, were not remarkably associ-
ated with ischemic stroke, which might have been due to
ethnic differences since most significant findings were
observed among Caucasian populations [26].
CCR2, resident on chromosome 3q21, transcribes the
receptor of MCP-1 which plays important roles in
extravasation and transmigration of monocytes under in-
flammatory conditions [5, 27]. There were no nominal
associations of CCR2 rs1799864 or rs1799865 with the
risk of ischemic stroke in our study. This result is con-
sistent with previous studies conducted in an Armenian
population but not in a Chinese Han population, since a
significant association was observed between CCR2 and
ischemic stroke only in the hypertensive group [28, 29].
The E-selectin gene, a member of the selectin superfam-
ily of adhesion molecules, is on chromosome 1q23-25. In
our study, E-selectin rs2076059 was significantly associ-
ated with ischemic stroke under the dominant model after
adjusting for covariates. E-selectin rs2076059 is in a non-
coding region. There is no doubt that polymorphisms
located in exon regions have higher probabilities of having
biological functions. However, we could not exclude the
possibility that polymorphisms in non-expression regionsrisk of ischemic stroke. The odds ratios (ORs) were adjusted for age,
art disease, and stroke family history. Estradiol levels were divided into
in female and male controls. The second quartile (Q2) of the polygenic
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phisms situated in an enhancer region consisting of coded
or uncoded sequences physically affect regulation of gene
expressions.
Because stroke is a complicated disease which is not
attributed to a single gene mutation, a PRS estimated by
a sum of trait-associated alleles across many genetic loci
and weighted by an effect size is more appropriate. A
PRS constructed according to the magnitudes of individ-
ual SNPs' effects would be most efficient when consider-
ing multiple loci in combination [30, 31]. In this study,
MCP-1, its receptor, CCR2, and E-selectin which are
prominently influenced by E2 were selected as candidate
genes. The PRS construction procedure of these three
candidate genes included eight SNPs, and MCP-1
rs1024611, CCR2 rs1799865, and E-selectin rs2076059
and rs5368 were chosen to build a PRS. Our findings
that the risk of developing a specific inflammation-related
disease might be influenced by a susceptibility profile are
consistent with previous studies, and reflect the combined
effects of multiple high-risk alleles [32, 33]. A PRS model
comprised of five variants in a Japanese study showed that
the OR for ischemic stroke was 1.75-fold in the highest
PRS quintile compared to the lowest [32]. Opherk et al.
further found a PRS to be associated with white matter
hyperintensity volume in cerebral small-vessel disease
[33]. In short, these findings suggest that a PRS can pro-
vide valuable information for individual risk assessments.
Estrogen is considered to have well-documented
neuroprotective effects in a variety of experimental and
clinical neurodegenerative disorders including stroke
[34, 35]. A mechanism to explain the anti-inflammatory
activity of E2 is through estrogen receptor-α (ERα),
which mediates inhibition of NF-κB transport [15].
Further, E2 can reduce MCP-1 and E-selectin expres-
sions in cell culture preparations [15, 36], in experimen-
tal animals [37, 11], and even in human studies [38].
Since estrogen has important gene-regulatory effects
[39], it was not surprising to find that subjects with a
low level of estradiol and a higher PRS had higher ische-
mic stroke risks.
Our data have some valuable strengths. First, this is
the first study to simultaneously investigate the effects of
estrogen and inflammatory genetic polymorphisms on
the risk of ischemic stroke. Second, the diagnostic cri-
teria of ischemic stroke were quite accurate since all pa-
tients were confirmed by CT or MRI. However, this
study has several potential limitations. First, this was a
case-control study design, and recruitment and survival
bias could not be neglected. Second, although this study
had nearly 80% power to detect a log-additive model
with an OR of 1.5, allelic frequencies of 10%, and an
interaction effect size of Rge = 2, other SNPs with ORs
of <1.5 may need a larger sample size to increase thestatistical power. Therefore, further studies with larger
sample sizes are warranted. Third, only SNPs of MCP-1,
CCR2, and E-selectin genes were selected to investigate
the relationship with ischemic stroke. Other SNPs of in-
flammatory genes might be associated with ischemic
stroke and must be further studied to clarify the role of
inflammatory genes and estrogen in ischemic stroke. Last,
although around 90% subjects were postmenopausal, we
could still measure the estradiol level especially in females
and found the effect of the hormone on the risk of
ischemic stroke.
Conclusions
Our results show that the PRS model composed of four
variants of inflammatory genes could identify those with
a high risk of ischemic stroke. Furthermore, the risk
worsened when subjects were exposed to low estradiol
levels. Future comprehensive evaluations of the PRS
with estradiol levels and additional lifestyle or environ-
mental risk factors should be considered.
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